Pharmacokinetics, Safety, and Tolerability of a Single 5‐Day Treatment of Tirbanibulin Ointment 1% in 100 cm2: A Phase 1 Maximal‐Use Trial in Patients with Actinic Keratosis.

MLA

DuBois, Janet, et al. “Pharmacokinetics, Safety, and Tolerability of a Single 5‐Day Treatment of Tirbanibulin Ointment 1% in 100 Cm2: A Phase 1 Maximal‐Use Trial in Patients with Actinic Keratosis.” Clinical Pharmacology in Drug Development, vol. 13, no. 2, Feb. 2024, pp. 208–18. EBSCOhost, https://doi.org/10.1002/cpdd.1368.

APA

DuBois, J., Jones, T. M., Lee, M. S., Falqués, M., Kiyasova, V., Jiménez, G., Otero, R., Jansat, J., Aubets, J., & Forconi, R. J. (2024). Pharmacokinetics, Safety, and Tolerability of a Single 5‐Day Treatment of Tirbanibulin Ointment 1% in 100 cm2: A Phase 1 Maximal‐Use Trial in Patients with Actinic Keratosis. Clinical Pharmacology in Drug Development, 13(2), 208–218. https://doi.org/10.1002/cpdd.1368

Chicago

DuBois, Janet, Terry M. Jones, Mark S. Lee, Meritxell Falqués, Vera Kiyasova, Gemma Jiménez, Raquel Otero, Josep‐M. Jansat, Jordi Aubets, and Rion James Forconi. 2024. “Pharmacokinetics, Safety, and Tolerability of a Single 5‐Day Treatment of Tirbanibulin Ointment 1% in 100 Cm2: A Phase 1 Maximal‐Use Trial in Patients with Actinic Keratosis.” Clinical Pharmacology in Drug Development 13 (2): 208–18. doi:10.1002/cpdd.1368.